What happened
Hanmi Pharm filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$297M (+23.14% year on year), operating profit of US$57M (+173.42% year on year) and net income of US$37.7M (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$297M |
|---|---|
| Revenue vs a year earlier | +23.14% |
| Operating profit | US$57M |
| Net income | US$37.7M |
| Period | Q4 2025 (consolidated) |
| Filed | 2026-02-05, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260205800771 → open original filing |
Source: DART. Information only, not investment advice.